Articles from Enigma Biomedical USA

Enigma Biomedical USA (EB USA) today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF), has awarded EB USA $2 million for the discovery and initial preclinical development of a novel α-synuclein Positron Emission Tomography (PET) Imaging biomarker. This funding is part of MJFF’s strategic research agenda focused on supporting objective tools to biologically measure and track the progression of Parkinson’s disease (PD) to improve clinical trial design.Misfolded α-synuclein — a protein that clumps in the brains of people who live with PD — is a fundamental hallmark of the disease resulting in its symptoms. A new staging framework aimed at defining PD and related neuronal α-synuclein diseases based on their underlying biology places conditions such as PD and dementia with Lewy bodies (DLB) along a shared continuum of progression — from disease risk to functional impairment — and underscores a standardized biological diagnosis.

Enigma Biomedical USA (EB USA) today announced formation of its Scientific Advisory Board (SAB), comprised of top tier physicians and scientists from around the globe, spanning areas of expertise from chemistry, biology to medicine associated with the assessment and ultimate treatment of neurodegenerative diseases, such as Alzheimer’s Disease.

Enigma Biomedical USA (EB) today announced a collaboration with Alamar Biosciences in the field of neurology. Through this collaboration, EB has a non-exclusive right to introduce Alamar’s protein detection and measurement technologies, including its ARGO™ HT instrument and NULISA™ reagent kits, to academic and pharma customers in the field of neurology research.

Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO). Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition. He will join Enigma at the beginning of March, 2024.